Drug Delivery to the Lung (DDL)

Upperton will be exhibiting at the Drug Delivery to the Lung (DDL) virtual conference from Wednesday 9th to Friday 11th December (UTC+), to showcase their pulmonary delivery capabilities and technical knowledge. Particularly our pulmonary scale up technique PulmoCraft

We are looking forward to meeting both new and existing clients on our stand. So if you have an API which requires formulation development or clinical manufacture, please contact us to book an appointment or alternatively drop by our exhibition stand to talk to Upperton’s team. 

Upperton Team

Richard Johnson
Founder & CEO

Dr Richard Johnson founded Upperton Pharma Solutions in August 1999, and continues to play a key role in the management and strategic development of the company. With over 30 years of experience in the pharmaceutical, biotechnology and drug delivery fields, Richard previously held senior management positions at Andaris Limited (Vectura) and Delta Biotechnology (now Albumedix). Richard holds an honours degree in Biology from University of York and a Ph.D. from the University of Warwick and has a proven track record in successfully developing innovative pharmaceutical products from early feasibility studies through to commercial products.

Ian Lafferty
Technical Director

Dr Ian Lafferty has recently joined Upperton Pharma Solutions as a Technical Consultant. Ian has 25 years’ technical and operational experience in early phase pharmaceutical development encompassing the formulation design, development, process optimisation and manufacture of a wide range of dosage forms including oral solids, inhaled powders, suspensions and injectables with a focus on challenging molecules, enabling technologies and high potent handling. He also has significant experience in facility design and management.

Ian has held senior roles at several emerging and growing CDMOs providing strategic and operational leadership to ensure excellence in all aspects of providing pharmaceutical services.

Shailesh Mistry
Senior Scientist

Shailesh is a science graduate with over 18 years of experience working within the Pharmaceutical industry in a variety of technical roles. Before joining Upperton in July 2017, he was a Senior Scientist at Co-Formulate, Omniceutica and Vectura where he worked on wide range of product development projects from the feasibility / concept stage right the way through to full scale GMP manufacture. At Upperton Shailesh oversees many client projects from early feasibility proof of concept studies, through formulation development, scale-up and technology transfer; with a particular expertise in inhaled product development, spray drying, analytical method development and HPLC. 

He studied Medical Science at the University of Birmingham and also held scientific roles at both 3M Healthcare and GlaxoSmithKline.

Jack Sorrell
Senior Scientist

Jack joined Upperton in 2015 from Critical Pharmaceuticals. He studied Medicinal and Biology Chemistry MSci at the University of Nottingham. His main areas of expertise include spray drying, analytical method development, and material and powder characterisation. Alongside his hands-on technical role, Jack leads a team of R&D Scientists conducting a range of experimental development activities across a number of dosage forms and provides his expertise to our clients.

Klara Fisken
Marketing & Communications Officer

Klara Fisken joined Upperton in 2018 after completing an MSc in Applied Biopharmaceutical, Biotechnology and Entrepreneurship from the University of Nottingham. As a Marketing Manager Klara is responsible for all activities related to Upperton’s marketing, branding, online presence and communication and also has a client facing role in supporting business development strategies. Whilst working at Upperton, Klara has gained front line experience and knowledge about the drug development pathway from early feasibility studies through to clinical manufacture. Klara has also gained first hand insight into the operational aspects of the pharmaceutical development industry and developed a thorough understanding of Upperton’s technical capabilities, strengths and credentials.

DDL Conference

The Drug Delivery to the Lungs (DDL) Conference provides an annual forum for scientists, academics, clinicians, regulatory and industry specialists involved in developing medicines for inhalation. Providing a full programme of lectures, access to scientific posters and an industry exhibition.